中文版 | English
题名

ORIGINAL RES EARCH Value of UGT2B7-161 Single Nucleotide Polymorphism in Predicting the Risk of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Who Underwent Pertuzumab Combined with Trastuzumab PSL

作者
通讯作者Li, Jian; Xu, Jin-Feng
发表日期
2022
DOI
发表期刊
EISSN
1178-7066
卷号15
摘要
Objective: To explore the value of uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7)-161 single nucleotide polymorphism in predicting the occurrence of cardiotoxicity in Chinese human epidermal growth factor 2 (HER-2) positive breast cancer patients who underwent pertuzumab combined with trastuzumab Therapy. Methods: Fifty patients with HER-2 positive breast cancer who planned to receive trastuzumab and pertuzumab therapy for more than four cycles were enrolled in this study, and blood samples were collected. Thirty healthy volunteers of matching ages were selected as the control group. Myocardial parameters such as global work index, global effective work, and global wasted work were measured before treatment (M0) and at the end of four cycles of treatment month three (M3). Blood samples were collected from patients at the M0 stage, and polymorphisms of the UGT2B7-161 gene were detected to evaluate the predictive ability of different gene phenotypes on the myocardial drug toxicity injury. Results: There were 35 myocardial work decreased events among 50 patients. There were 24 (47.3%), 15 (40.8%), and 11 (11.8%) patients carrying UGT2B7-161 CC, CT, and TT genotypes, respectively. The occurrence of myocardial work decreased was decreased in UGT2B7-161 TT and CT genotypes (12.5%) compared with CC genotype (41.7%) with statistical significance (P < 0.001). Multivariate logistic regression model analysis exhibited that UGT2B7-161 genotypes, body mass index, and cardiac troponin I were independent factors influencing the risk of cardiotoxicity. Conclusion: UGT2B7-161 single nucleotide polymorphism is a potential predictive factor for cardiotoxicity in HER-2 positive breast cancer patients receiving trastuzumab and pertuzumab dual-targeted drug therapy.
关键词
相关链接[来源记录]
收录类别
语种
英语
学校署名
通讯
资助项目
Sanming Cultivation Project of Medicine in Shenzhen[SYLY201903]
WOS研究方向
Pharmacology & Pharmacy
WOS类目
Pharmacology & Pharmacy
WOS记录号
WOS:000772905200001
出版者
来源库
Web of Science
引用统计
被引频次[WOS]:4
成果类型期刊论文
条目标识符http://sustech.caswiz.com/handle/2SGJ60CL/328453
专题南方科技大学第一附属医院
作者单位
1.Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Ultrasound, Shenzhen 518020, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen 518020, Guangdong, Peoples R China
3.Southern Univ Sci & Technol, Affiliated Hosp 1, Clin Med Coll 2, Jinan Univ,Dept Med Oncol,Shenzhen Peoples Hosp, Shenzhen 518020, Guangdong, Peoples R China
4.North Sichuan Med Coll, Affiliated Nanchong Cent Hosp, Dept Ultrasound, Nanchong, Peoples R China
第一作者单位南方科技大学第一附属医院
通讯作者单位南方科技大学第一附属医院
推荐引用方式
GB/T 7714
Li, Jian,Luo, Hui,Liu, Ying-Ying,et al. ORIGINAL RES EARCH Value of UGT2B7-161 Single Nucleotide Polymorphism in Predicting the Risk of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Who Underwent Pertuzumab Combined with Trastuzumab PSL[J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE,2022,15.
APA
Li, Jian.,Luo, Hui.,Liu, Ying-Ying.,Chen, Li-Xin.,Zhu, Mei-Qin.,...&Xu, Jin-Feng.(2022).ORIGINAL RES EARCH Value of UGT2B7-161 Single Nucleotide Polymorphism in Predicting the Risk of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Who Underwent Pertuzumab Combined with Trastuzumab PSL.PHARMACOGENOMICS & PERSONALIZED MEDICINE,15.
MLA
Li, Jian,et al."ORIGINAL RES EARCH Value of UGT2B7-161 Single Nucleotide Polymorphism in Predicting the Risk of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Who Underwent Pertuzumab Combined with Trastuzumab PSL".PHARMACOGENOMICS & PERSONALIZED MEDICINE 15(2022).
条目包含的文件
条目无相关文件。
个性服务
原文链接
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
导出为Excel格式
导出为Csv格式
Altmetrics Score
谷歌学术
谷歌学术中相似的文章
[Li, Jian]的文章
[Luo, Hui]的文章
[Liu, Ying-Ying]的文章
百度学术
百度学术中相似的文章
[Li, Jian]的文章
[Luo, Hui]的文章
[Liu, Ying-Ying]的文章
必应学术
必应学术中相似的文章
[Li, Jian]的文章
[Luo, Hui]的文章
[Liu, Ying-Ying]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
[发表评论/异议/意见]
暂无评论

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。